Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05840107 | Study of FasT CAR-T GC012F Injection NDMM Patients | unknown | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05904522 | Histopathological Changes in Mycosis Fungoides | unknown | N/A | 10 | Bezmialem Vakif UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06255639 |
| Biomechanical and Metabolic Assessment Pre and Post Vertebroplasty in Multiple Myeloma Patients With Vertebral Collapse |
| unknown |
| — |
| 20 |
| Centro di Riferimento Oncologico - AvianoOTHER |
| 1 |
| Feb 13, 2024 |
| clinicaltrials |
| NCT06255847 | Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM | unknown | Phase 2 | 43 | Shanxi Bethune HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT03818685 | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease(BreastImmune03) | unknown | Phase 2 | 95 | Centre Leon BerardOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05028933 | IMC001 for Clinical Research on Advanced Digestive System Malignancies | unknown | Phase 1 | 48 | Zhejiang UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT06254547 | Leaderboard Influence on Self-Regulated Training in a Gamified Dermoscopy Training App | unknown | N/A | 150 | Herlev HospitalOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT01819480 | Efficacy and Safety of TORS for SCCA | unknown | N/A | 110 | Katherine L FedderOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT03274479 | PBF-1129 in Patients With NSCLC | unknown | Phase 1 | 18 | Palobiofarma SLINDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT03462888 | Clinico-biological Study/Characterization of Rhabdomyosarcoma in Adolescents and Young Adults, 15-25-year-old Patients(RMS-AJA-1701) | unknown | — | 113 | Centre Oscar LambretOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04844385 | Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 124 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05163249 | Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC(FLOWERS) | unknown | Phase 2 | 44 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05602259 | PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC).(PROTEON) | unknown | N/A | 200 | Centre Hospitalier Universitaire de LiegeOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05842317 | Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC | unknown | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06250829 | Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer(Pre-PLaN) | unknown | — | 60 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT03599960 | Combination Chemotherapy in Patients With Newly Diagnosed BPDCN(LpDessai) | unknown | Phase 2 | 26 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05875428 | Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | unknown | Phase 2 | 104 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05893810 | Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis | unknown | Phase 3 | 176 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06241391 | Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas | unknown | N/A | 35 | All India Institute of Medical Sciences, BhubaneswarOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT01871454 | Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers | unknown | Phase 2 | 59 | University of LouisvilleOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03549273 | Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions | unknown | Phase 2 | 62 | Catalysis SLINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04582487 | Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL | unknown | N/A | 32 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04731974 | Acute Concussion and Melatonin | unknown | Phase 2 | 254 | Children's National Research InstituteOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05173298 | Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab(HCC) | unknown | — | 100 | CHA UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05234684 | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma(BELIEVE-01) | unknown | Phase 3 | 150 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06246006 | Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia(MPL - NPM) | unknown | — | 30 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06246903 | INTER-PATHOLOGIST READER STUDY | unknown | — | 500 | Orlucent, IncINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06247293 | Surgical Resection Combined With Intraperitoneal Hyperthermic Chemotherapy | unknown | — | 100 | Zhujiang HospitalOTHER | 0 | Feb 7, 2024 | clinicaltrials |
| NCT06031818 | Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Prediction | unknown | — | 80 | Maastricht UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06234553 | Application of Radiomics in the Diagnosis and Treatment Prediction of Pituitary Adenoma(RIPA) | unknown | — | 200 | Beijing Tiantan HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06243185 | Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors | unknown | Phase 2 | 30 | Fengzhi FengOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06244446 | Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma. | unknown | — | 40 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06241105 | Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 69 | Peking Union Medical College HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT04161287 | Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE | unknown | — | 330 | Beijing 302 HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05526573 | Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions | unknown | — | 148 | Azienda Sanitaria-Universitaria Integrata di UdineOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05743504 | Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | unknown | Phase 1 / Phase 2 | 32 | National Taiwan University HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06238336 | Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours | unknown | Phase 2 / Phase 3 | 30 | Shanxi Bethune HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06239623 | ERK Inhibitor JSI-1187 in Advanced Solid Tumors | unknown | Phase 1 | 60 | JS InnoPharm, LLCINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03799939 | Chimney Trial of Parastomal Hernia Prevention | unknown | N/A | 141 | University of OuluOTHER | 2 | Feb 1, 2024 | clinicaltrials |
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | unknown | Phase 1 / Phase 2 | 69 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04560894 | SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 405 | Sinocelltech Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04823741 | Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma(SCITH-MESO) | unknown | — | 30 | Hospices Civils de LyonOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05212779 | Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease | unknown | — | 45 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05266937 | Atezolizumab Plus CArboplatin Plus Nab-paclitaxel | unknown | Phase 2 | 49 | Consorzio OncotechOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06208319 | Development and Evaluation of an Artificial Intelligence Tool for Colposcopy Assistance(IACOL) | unknown | — | 1,000 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Feb 1, 2024 | clinicaltrials |
| NCT06235918 | Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 30 | Xiang LuOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06236360 | Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet(MINI-MD) | unknown | N/A | 30 | University Hospital RijekaOTHER | 1 | Feb 1, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Feb 13, 2024source: clinicaltrials